Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.05 [1.7, 2.48]
8 studies · 3791 participants
Low
OR 1.51 [1.13, 2]
3 studies · 1196 participants
High
OR 2.6 [2.01, 3.35]
5 studies · 2595 participants
Low
Grade 3 to 4 neutropenia · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Peritoneal lavage vs. open necrosectomy · people with necrotising pancreatitis
It is very uncertain whether the intervention changes peritoneal lavage vs. open necrosectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Minimally invasive step‐up approach vs. open necrosectomy · people with necrotising pancreatitis
The intervention may leads to lower minimally invasive step‐up approach vs. open necrosectomy (low certainty).
1 finding from 1 review
Intervention not reported
Peritoneal lavage vs. open necrosectomy · people with necrotising pancreatitis
It is very uncertain whether the intervention changes peritoneal lavage vs. open necrosectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Minimally invasive step‐up approach vs. open necrosectomy · people with necrotising pancreatitis
It is very uncertain whether the intervention changes minimally invasive step‐up approach vs. open necrosectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Delayed open necrosectomy vs. early open necrosectomy · people with necrotising pancreatitis
It is very uncertain whether the intervention changes delayed open necrosectomy vs. early open necrosectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Minimally invasive step‐up approach vs. open necrosectomy · people with necrotising pancreatitis
It is very uncertain whether the intervention changes minimally invasive step‐up approach vs. open necrosectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Peritoneal lavage vs. open necrosectomy · people with necrotising pancreatitis
It is very uncertain whether the intervention changes peritoneal lavage vs. open necrosectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Open surgical drainage versus EUS‐guided drainage · patients with pancreatic pseudocysts
It is very uncertain whether the intervention changes open surgical drainage versus EUS‐guided drainage (very low certainty).
1 finding from 1 review
Intervention not reported
Open surgical drainage versus EUS‐guided drainage · patients with pancreatic pseudocysts
1 finding from 1 review
Intervention not reported
Open surgical drainage versus EUS‐guided drainage Scale from: 0 to 100. Higher indicates better · patients with pancreatic pseudocysts
1 finding from 1 review
Intervention not reported
Major adverse effects ‐ Neutropenia · people with non‐transfusion dependent beta thalassaemia
It is very uncertain whether the intervention changes major adverse effects ‐ Neutropenia (very low certainty).
1 finding from 1 review
Intervention not reported
Major adverse effects ‐ Thrombocytopenia · people with non‐transfusion dependent beta thalassaemia
It is very uncertain whether the intervention changes major adverse effects ‐ Thrombocytopenia (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review